Frieren: Before Journey's End isn't the only creative high fantasy anime with demons, extensive folklore, and beautiful, ...

A character's survival in Baldur’s Gate 3 felt like a loss—until the epilogue revealed that healing doesn’t always look like ...

The researchers who developed the system, called Centaur, fine-tuned a large language model (LLM) using a massive set of data ...

Forty years after the first effort to extract mummy DNA, researchers have finally generated a full genome sequence from an ...

CAMBRIDGE, Mass., June 23, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy ...

Seattle companies Banzai and Seeq announce C-suite executives while former Wizards of the Coast leaders disclose new moves.

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss Patients ...

Scholar Rock, a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy and additional severe and debilitating ...

In the early 2000s, Dr. Michele Puryear, an expert in pediatric genetics, founded the Advisory Committee on Heritable Disorders in Newborns and Children while working at the Department of Health ...

CAMBRIDGE, Mass., June 23, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy ...